AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent

BeiGene Ltd BGNE says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc ABBV company.

As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa.

"BeiGene's work is original, and we will vigorously defend against all allegations of patent infringement," the company said.

Imbruvica (ibrutinib) is a once-daily oral medication jointly developed and commercialized by Janssen Biotech Inc, a unit of Johnson & Johnson JNJ and Pharmacyclics.

BeiGene said that most recently, the ALPINE study, a head-to-head comparison between Brukinsa and Imbruvica in R/R CLL/SLL, demonstrated Brukinsa's superior efficacy (PFS and ORR) and safety (atrial fibrillation) over Imbruvica.

The study also reported zero sudden cardiac death events for Brukinsa versus a 1.9% rate for Imbruvica. 

Global sales of Brukinsa reached $211.4 million for Q1 2023, compared to $104.3 million a year ago.

Price Action: BGNE shares are down 0.37% at $207.36 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareLegalMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!